Chief Patron: Dunnavant
Pharmaceutical Processor Transitional Cannabis Sales

Item 301 #2s

Language
Page 311, line 42, strike "$37,784,871" and insert "$37,884,871".
Page 311, line 42, strike "$38,153,945" and insert "$38,253,945".

Explanation

(This amendment provides $100,000 each year from the nongeneral fund for the costs associated with the implementation of legislation to be considered in the 2022 Session that establishes a framework for transitional cannabis sales by pharmaceutical processors.)